peptidylprolyl isomerase A pseudogene 25Genealiases: []
Q-omics provides the consensus-scored PPIAP25 profile across patient tissues and cancer cell-line models. PPIAP25 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPIAP25 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, PPIAP25 RNA expression shows 6,220 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, HNSC, and STAD as cancer lineages where PPIAP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP25 survival associations across molecular data types. PPIAP25 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP25 RNA expression–survival associations across cancer types. High PPIAP25 expression shows unfavorable associations in UVM, MESO, ACC and STAD, but favorable associations in LUSC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPIAP25 RNA expression.
This table summarizes PPIAP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP25 shows lower tumor expression in LUSC and higher tumor expression in HNSC, COAD, PRAD, LIHC and KIRC. The HNSC box plot shows higher PPIAP25 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p = .038).
This table shows molecular features associated with PPIAP25 in patient tissues and cancer cell lines. In patient samples, PPIAP25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
